Print

Orexo AB Release: First Patient Dosed in New Phase III Study Targeted Towards a Future Clinical Indication Expansion for Zubsolv  
6/17/2013 9:03:28 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Uppsala, Sweden – June 17, 2013 - Orexo AB announces today that the first patient has been dosed with Zubsolv in a phase III study for a new clinical indication for Zubsolv.

Help employers find you! Check out all the jobs and post your resume.

//-->